Soleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference
Rhea-AI Summary
Soleno Therapeutics (NASDAQ: SLNO), a clinical-stage biopharmaceutical company focused on rare disease treatments, has announced its participation in the 2024 Cantor Global Healthcare Conference. The company's management will present on Tuesday, September 17, 2024, at 8:00 AM Eastern Time.
Investors and interested parties can access a live audio webcast of the presentation through Soleno's website. The presentation will also be available for replay in the Investors section at www.soleno.life. This conference provides Soleno with an opportunity to showcase its progress in developing novel therapeutics for rare diseases to a global audience of healthcare industry professionals and investors.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, SLNO gained 0.25%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
REDWOOD CITY, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will present at the 2024 Cantor Global Healthcare Conference on Tuesday, September 17, 2024, at 8:00 AM Eastern Time.
A live audio webcast and replay of the presentation will be available in the Investors section on the Company’s website at www.soleno.life.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. An NDA for its lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS) is currently under review by the FDA and was granted Priority Review. For more information, please visit www.soleno.life.
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578